Authors

LIANG CANCAN1, WANG HAIKUN2, KE YUE1, JI WENJING1

Departments

1Department of Digestive Internal Medicine, The Second Affiliated Hospital of Xinjiang Medical University, Xinjiang, 830000, China - 2Department of Digestive Internal Medicine, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, 830000, China

Abstract

Purpose: To investigate the expressions of TLR4 and MyD88, and their correlations with clinicopathological features in patients with colorectal cancer.

Methods: A total of 234 patients were selected for this study and divided into two groups of 117 patients each, namely: study group (patients with colorectal cancer over a period of two years) and control (patients with normal intestinal mucosal tissues). They consisted of 68 males and 49 females aged between 29 and 67 years (mean age = 52 years). Patients in the study group were staged using TNM staging criteria for colorectal cancer. Immunohistochemistry was used to determine the degree of expressions of Toll-like receptor 4 (TLR4) and myeloid differentiation factor (MyD88) in colorectal cancer and normal mucosal tissues. The relationship between the expressions of TLR4 and MyD88, and clinical characteristics and prognosis was also assessed..

Results: The expressions of TLR4 and MyD88 in colorectal cancer tissues were significantly higher (p < 0.05), when compared to control, and were positively correlated with TNM staging, liver metastasis and vascular invasion. Patients with low expressions of TLR4 and MyD88 had significantly longer (p < 0.05) survival time than those with high expressions, and the expressions of TLR4 and MyD88, and TNM staging had significant impact (p < 0.05) on the prognosis of colorectal cancer.

Conclusion: There is a positive correlation between the expressions of TLR4 and MyD88, and clinic-pathological features such as TNM staging, metastasis, and vascular invasion of patients with colorectal cancer.

Keywords

TLR4, MyD88, Colorectal cancer, Clinico-pathological features, Prognosis

DOI:

10.19193/0393-6384_2018_6_300